Germany: IQWiG Finds Melanoma Drug Extends Life
A comparator study undertaken by Germany's Institute for Quality and Economy in Healthcare (IQWiG) has found the drug ipilimumab provides substantial additional benefit to patients suffering from advanced melanoma.
In a three-pronged randomized clinical trial against "best supportive care", IQWiG found the drug extended life expectancy by 10 months as compared to 6.5 months with the comparator.
The drug, however, is not without serious immune-mediated side effects as well.
Read more:
IQQiG - Ipilimumab - Nutzenbewertung gemäß § 35a SGB V